Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 35; no. 1; p. 38
• Main Authors: Sun, Bing, Song, San-tai, Jiang, Ze-fei, Wang, Tao, Zhang, Shao-hua, Meng, Xiang-ying, Li, Xiao-bing, Yu, Cheng-ze, Wu, Shi-kai
• Format: Journal Article
• Language: Chinese
• Published: China 01.01.2013
• Subjects: Adult; Aged; Aged, 80 and over; Anthracyclines - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Bridged-Ring Compounds - administration & dosage; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy - methods; Proportional Hazards Models; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Remission Induction; Retrospective Studies; Taxoids - administration & dosage; Tumor Burden
• ISSN: 0253-3766
• DOI: 10.3760/cma.j.issn.0253-3766.2013.01.008

To analyze the factors affecting pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients. A retrospective cohort study was carried out to analyze the clinical data of 141 breast cancer patients treated with neoadjuvant chemotherapy. The factors affecting pCR and the changes of tumor receptor status before and after treatment were analyzed. Among all the 141 patients, 21 patients (14.9%) achieved pCR. The rate of pCR achieved by regimens of anthracycline combined with taxane was higher (16.8%, 19/113) than that by anthracycline-containing regimens (7.1%, 1/14). The dose intensity of anthracycline had a significant correlation with pCR rate (P < 0.05). The pCR rate in the relative dose intensity of taxane ≥ 0.85 arm was higher than that of < 0.85 arm (P = 0.02). Eighty patients (56.7%) had completed more than 4 cycles of chemotherapy and the median time to achieve pCR was 6 (3 to 10) cycles. The pCR rate had a significant difference between patients < 6 and ≥ 6 cycles (7.1